1. Home
  2. DETX vs GTBP Comparison

DETX vs GTBP Comparison

Compare DETX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Defense Holdings Ltd. Common Shares

DETX

Liberty Defense Holdings Ltd. Common Shares

N/A

Current Price

$3.62

Market Cap

20.5M

ML Signal

N/A

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

N/A

Current Price

$0.29

Market Cap

17.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DETX
GTBP
Founded
N/A
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.5M
17.7M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
DETX
GTBP
Price
$3.62
$0.29
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
15.8K
437.8K
Earning Date
N/A
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.75
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.78
$0.26
52 Week High
$4.25
$1.48

Technical Indicators

Market Signals
Indicator
DETX
GTBP
Relative Strength Index (RSI) 50.37 35.03
Support Level $2.78 $0.27
Resistance Level $4.24 $0.47
Average True Range (ATR) 0.34 0.02
MACD 0.08 0.00
Stochastic Oscillator 49.66 0.75

Price Performance

Historical Comparison
DETX
GTBP

About DETX Liberty Defense Holdings Ltd. Common Shares

Liberty Defense Holdings Ltd is engaged in the development and commercialization of security detection technologies such as airports, stadiums, schools, and more. The company's Hexwave product utilizes millimeter wave technology and Advanced 3D imaging to detect concealed threats. In addition to HEXWAVE, the company has licensed High-Definition Advanced Imaging Technology (HD-AIT) for body and shoe scanning. The Company operates through three distinct segments: Corporate, HEXWAVE, and Contract. The company generates the majority of its revenue from the Contract segment. Geographically, the company generates the majority of its revenue from the United States.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: